SCHEMBL182874

SCHEMBL182874

COc1ccc(-c2ccc3nc(N)nc(-c4ccc(OC)c(OC)c4)c3c2)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.48
PDGFRA P16234 1/20 0.48
DHFR P00374 3/20 0.47
KIT P10721 2/20 0.47
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ADORA1 P30542 1/20 0.45
PIK3CA P42336 2/20 0.45
MTOR P42345 2/20 0.45
PIK3CD O00329 1/20 0.45
PIK3CB P42338 1/20 0.45
PIK3CG P48736 1/20 0.45
ADORA2A P29274 3/20 0.44
HSP90AB1 P08238 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182850 0.92 DHFR (0.53) PDGFRBPDGFRADHFRKDM4EMEN1
SCHEMBL183022 0.86 SQSTM1 (0.48) DHFRKITALDH1A1KDM4EMEN1
SCHEMBL182897 0.85 ADORA1 (0.48) PDGFRBPDGFRADHFRALDH1A1KDM4E
SCHEMBL182575 0.85 ADORA1 (0.52) DHFRALDH1A1KDM4EMEN1KMT2A
SCHEMBL183029 0.83 PIK3CA (0.51) PDGFRBPDGFRADHFRKITL3MBTL1
SCHEMBL1879036 0.82 HSP90AB1 (0.65) DHFRKDM4EMEN1KMT2AL3MBTL1
SCHEMBL183015 0.82 L3MBTL1 (0.51) DHFRKDM4EL3MBTL1ADORA1ADORA2A
SCHEMBL182901 0.82 PIK3CA (0.51) PDGFRBPDGFRADHFRKITL3MBTL1
SCHEMBL183072 0.82 FYN (0.54) DHFRL3MBTL1ADORA1PIK3CAMTOR
SCHEMBL182810 0.81 PIK3CA (0.49) PDGFRBPDGFRADHFRKITL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP claimed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US claimed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO claimed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA PDGFRB 726/4885PDGFRA 739/4885DHFR 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.